Literature DB >> 23746265

Assessing quality of life of nursing home residents with dementia: feasibility and limitations in patients with severe cognitive impairment.

María Crespo1, Carlos Hornillos, M Mar Gómez.   

Abstract

BACKGROUND: The Quality of Life-Alzheimer's Disease Scale (QOL-AD) is a reliable and valid self-report measure for assessing quality of life (QoL) in people with dementia in long-term care settings, but little is known yet about the number of patients with severe cognitive impairment who are able to complete this measure, and the characteristics of those unable to do so. The aim of the study is to advance knowledge of these issues.
METHODS: Data on residents with dementia were collected from 11 nursing homes. The QOL-AD residential version was directly applied to residents with dementia diagnosis and Mini-Mental State Examination scores under 27, randomly selected in each center. Residents' QoL was further assessed from the perspective of some close relative and some staff member. Altogether, 102 data sets from residents, 184 from relatives, and 197 from staff members were collected. An analysis of the characteristics of completers versus non-completers regarding levels of cognitive impairment was carried out.
RESULTS: People with dementia in long-term care are able to report their QoL. The QOL-AD completion rate decreases as the cognitive impairment level increases; non-completion is associated with greater overall impairment. About 30% of residents with severe cognitive impairment could self-report on their QoL with acceptable reliability.
CONCLUSIONS: QoL self-rating should be the first-line option when assessing residents with severe cognitive impairment. For those that are not able to complete self-report measures, proxies' report could be an alternative, although the development of other assessment procedures (e.g. observational) should be considered.

Entities:  

Mesh:

Year:  2013        PMID: 23746265     DOI: 10.1017/S1041610213000823

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  7 in total

1.  Do Cognitively Impaired Elderly Patients with Cancer Respond Differently on Self-reported Symptom Scores? A 5-Year Retrospective Analysis.

Authors:  Doris Ka Ying Miu; Kai Yin Lam; Chung On Chan
Journal:  Indian J Palliat Care       Date:  2022-01-20

2.  Characteristics Associated with Quality of Life in Long-Term Care Residents with Dementia: A Cross-Sectional Study.

Authors:  Maartje S Klapwijk; Monique A A Caljouw; Marjoleine J C Pieper; Jenny T van der Steen; Wilco P Achterberg
Journal:  Dement Geriatr Cogn Disord       Date:  2016-09-27       Impact factor: 2.959

Review 3.  Identifying the components of clinical vignettes describing Alzheimer's disease or other dementias: a scoping review.

Authors:  Harkanwal Randhawa; Aalim Jiwa; Mark Oremus
Journal:  BMC Med Inform Decis Mak       Date:  2015-07-15       Impact factor: 2.796

4.  A comparison of health utility scores calculated using United Kingdom and Canadian preference weights in persons with alzheimer's disease and their caregivers.

Authors:  Mingying Fang; Mark Oremus; Jean-Eric Tarride; Parminder Raina
Journal:  Health Qual Life Outcomes       Date:  2016-07-18       Impact factor: 3.186

5.  Development of Clinical Vignettes to Describe Alzheimer's Disease Health States: A Qualitative Study.

Authors:  Mark Oremus; Feng Xie; Kathryn Gaebel
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

6.  Can the general public use vignettes to discriminate between Alzheimer's disease health states?

Authors:  Mark Oremus; Feng Xie; Eleanor Pullenayegum; Kathryn Gaebel
Journal:  BMC Geriatr       Date:  2016-02-03       Impact factor: 3.921

7.  A Computer-Assisted Personal Interview App in Research Electronic Data Capture for Administering Time Trade-off Surveys (REDCap): Development and Pretest.

Authors:  Mark Oremus; Anis Sharafoddini; Gian Paolo Morgano; Xuejing Jin; Feng Xie
Journal:  JMIR Form Res       Date:  2018-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.